JAK2 V617F and beyond: Role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms

Expert Review of Hematology

Volumn 3, Issue 3, 2010, Pages 323-337

  Oh, Stephen T ^a   Gotlib, Jason ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Essential thrombocythemia; JAK STAT; JAK2 V617F; LNK; Mpl; Myeloproliferative neoplasm; Polycythemia vera; Primary myelofibrosis; TET2

Indexed keywords

CBL PROTEIN; JANUS KINASE 2; STAT PROTEIN;

APOPTOSIS; CANCER GENETICS; DNA DAMAGE; GENE; GENE FUNCTION; HUMAN; JAK2 GENE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; THROMBOCYTHEMIA;

ALLELES; ANIMALS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; JANUS KINASE 2; MICE; MUTATION; PHENOTYPE; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 77953529304     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.28     Document Type: Review

References (124)

1. Ania BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ 3rd. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am. J. Hematol. 47(2), 89-93 (1994).
2. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am. J. Hematol. 61(1), 10-15 (1999).
3. Tefferi A, Vardiman J. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22(1), 14-22 (2008).
4. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 6(4), 372-375 (1951).
5. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N. Engl. J. Med. 295(17), 913-916 (1976).
6. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 58(5), 916-919 (1981).
7. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 51(2), 189-194 (1978).
8. Prchal JF, Axelrad AA. Letter: Bone-marrow responses in polycythemia vera. N. Engl. J. Med. 290(24), 1382 (1974).
9. el Kassar N, Hetet G, Li Y, Briere J, Grandchamp B. Clonal analysis of haemopoietic cells in essential thrombocythaemia. Br. J. Haematol. 90(1), 131-137 (1995).
10. Tsukamoto N, Morita K, Maehara T et al. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement. Br. J. Haematol. 86(2), 253-258 (1994).
11. Dai CH, Krantz SB, Dessypris EN, Means RT, Horn ST, Gilbert HS. Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 80(4), 891-899 (1992).
12. Dai CH, Krantz SB, Means RT, Horn ST, Gilbert HS. Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3. J. Clin. Invest. 87(2), 391-396 (1991).
13. Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle 6(5), 550-566 (2007).
14. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. JAK2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93(3), 397-409 (1998).
15. Parganas E, Wang D, Stravopodis D et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93(3), 385-395 (1998).
16. Ihle J, Gilliland D. Jak2: normal function and role in hematopoietic disorders. Curr. Opin. Genet. Develop. 17(1), 8-14 (2007).
17. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285(1-2), 1-24 (2002).
18. Valentino L, Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem. Pharmacol. 71(6), 713-721 (2006).
19. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N. Engl. J. Med. 338(9), 572-580 (1998).
20. Roder S, Steimle C, Meinhardt G, Pahl HL. STAT3 is constitutively active in some patients with polycythemia rubra vera. Experiment. Hematol. 29(6), 694-702 (2001).
21. Komura E, Chagraoui H, Mansat de Mas V et al. Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression. Experiment. Hematol. 31(7), 622-630 (2003).
22. Ugo V, Marzac C, Teyssandier I et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Experiment. Hematol. 32(2), 179-187 (2004).
23. Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464), 1054-1061 (2005).
24. James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037), 1144-1148 (2005). (Pubitemid 40663494)
25. Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352(17), 1779-1790 (2005). (Pubitemid 40570926)
26. Levine R, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4), 387-397 (2005).
27. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Experiment. Hematol. 30(3), 229-236 (2002).
28. Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk. Lymphoma 49(3), 388-397 (2008).
29. Levine R, Wernig G. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematology Am. Soc. Hematol. Educ. Program. 233-239, 510 (2006).
30. Bumm T, Elsea C, Corbin A et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 66(23), 11156-11165 (2006).
31. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108(5), 1652-1660 (2006).
32. Shide K, Shimoda H, Kumano T et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 22(1), 87-95 (2008).
33. Tiedt R, Hao-Shen H, Sobas MA et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111(8), 3931-3940 (2008).
34. Xing S, Wanting T, Zhao W et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 111(10), 5109-5117 (2008).
35. Vannucchi A, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22(7), 1299-1307 (2008).
36. Antonioli E, Guglielmelli P, Poli G et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 93(1), 41-48 (2008).
37. Vannucchi A, Antonioli E, Guglielmelli P et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia 21(9), 1952-1959 (2007).
38. Tefferi A, Strand J, Lasho T et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 21(9), 2074-2075 (2007). (Pubitemid 47299994)
39. Kittur J, Knudson R, Lasho T et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 109(11), 2279-2284 (2007). (Pubitemid 46801558)
40. Campbell PJ, Griesshammer M, Döhner K et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107(5), 2098-2100 (2006).
41. Guglielmelli P, Barosi G, Specchia G et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 114(8), 1477-1483 (2009).
42. Tefferi A, Lasho T, Huang J et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 22(4), 756-761 (2008).
43. Tefferi A, Lasho T, Schwager SM et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br. J. Haematol. 131(3), 320-328 (2005). (Pubitemid 43899664)
44. Delhommeau F, Dupont S, Tonetti C et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 109(1), 71-77 (2007).
45. Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 108(9), 3128-3134 (2006).
46. Larsen TS, Christensen J, Hasselbalch H, Pallisgaard N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br. J. Haematol. 136(5), 745-751 (2007).
47. Jamieson CH, Gotlib J, Durocher JA et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc. Natl Acad. Sci. USA 103(16), 6224-6229 (2006).
48. James C, Mazurier F, Dupont S et al. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood 112(6), 2429-2438 (2008).
49. Wernig G, Mercher T, Okabe R, Levine R, Lee BH, Gilliland DG. Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107(11), 4274-4281 (2006).
50. Zaleskas V, Krause DS, Lazarides K et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 1(1), e18 (2006).
51. Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 111(5), 2785-2789 (2008).
52. Jones AV, Chase A, Silver RT et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat. Genet. 41(4), 446-449 (2009).
53. Kilpivaara O, Mukherjee S, Schram AM et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat. Genet. 41(4), 455-459 (2009).
54. Olcaydu D, Harutyunyan A, Jager R et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat. Genet. 41(4), 450-454 (2009).
55. Campbell P, Baxter E, Beer P et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108(10), 3548-3555 (2006).
56. Theocharides A, Boissinot M, Girodon F et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110(1), 375-379 (2007).
57. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108(7), 2435-2437 (2006).
58. Nussenzveig RH, Swierczek SI, Jelinek J et al. Polycythemia vera is not initiated by JAK2V617F mutation. Experiment. Hematol. 35(1), 32-38 (2007).
59. Lambert JR, Everington T, Linch DC, Gale RE. In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood 114(14), 3018-3023 (2009).
60. Dupont S, Masse A, James C et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 110(3), 1013-1021 (2007).
61. Delhommeau F, Dupont S, Della Valle V et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360(22), 2289-2301 (2009).
62. Abdel-Wahab O, Mullally A, Hedvat C et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114(1), 144-147 (2009).
63. Tefferi A, Pardanani A, Lim KH et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23(5), 905-911 (2009).
64. Viguié F, Aboura A, Bouscary D et al. Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? Leukemia 19(8), 1411-1415 (2005).
65. Abdel-Wahab O, Manshouri T, Patel J et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 70(2), 447-452 (2010).
66. Tefferi A, Lim KH, Abdel-Wahab O et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 23(7), 1343-1345 (2009).
67. Jankowska AM, Szpurka H, Tiu RV et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/ myeloproliferative neoplasms. Blood 113(25), 6403-6410 (2009).
68. Langemeijer SM, Kuiper RP, Berends M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 41(7), 838-842 (2009).
69. Mohamedali AM, Smith AE, Gaken J et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J. Clin. Oncol. 27(24), 4002-4006 (2009).
70. Tefferi A, Levine RL, Lim KH et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 23(5), 900-904 (2009).
71. Lorsbach R, Moore J, Mathew S, Raimondi S, Mukatira S, Downing J. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 17(3), 637-641 (2003).
72. Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H, Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11) (q22;q23). Cancer Res. 62(14), 4075-4080 (2002).
73. Tahiliani M, Koh KP, Shen Y et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324(5929), 930-935 (2009).
74. Scott LM, Tong W, Levine R et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356(5), 459-468 (2007).
75. Pardanani A, Lasho T, Finke C, Hanson C, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 21(9), 1960-1963 (2007).
76. Pietra D, Li S, Brisci A et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 111(3), 1686-1689 (2008).
77. Wang Y, Vandris K, Jones A et al. JAK2 Mutations are present in all cases of polycythemia vera. Leukemia 22(6), 1289-1289 (2008).
78. Arcasoy MO, Degar BA, Harris KW, Forget BG. Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood 89(12), 4628-4635 (1997).
79. Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prchal JT. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 90(5), 2057-2061 (1997).
80. Pikman Y, Lee BH, Mercher T et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3(7), e270 (2006).
81. Pardanani A, Levine R, Lasho T et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 108(10), 3472-3476 (2006).
82. Croker B, Kiu H, Nicholson S. SOCS regulation of the JAK/STAT signalling pathway. Semin. Cell Dev. Biol. 19(4), 414-422 (2008).
83. O'Sullivan LA, Liongue C, Lewis RS, Stephenson SE, Ward AC. Cytokine receptor signaling through the JAK- STAT-SOCS pathway in disease. Mol. Immunol. 44(10), 2497-2506 (2007).
84. Endo TA, Masuhara M, Yokouchi M et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387(6636), 921-924 (1997).
85. Sasaki A, Yasukawa H, Suzuki A et al. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4(6), 339-351 (1999).
86. Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG. SOCS-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol. Cell Biol. 21(10), 3547-3557 (2001).
87. Ungureanu D, Saharinen P, Junttila I, Hilton DJ, Silvennoinen O. Regulation of JAK2 through the ubiquitin-proteasome pathway involves phosphorylation of JAK2 on Y1007 and interaction with SOCS-1. Mol. Cell Biol. 22(10), 3316-3326 (2002).
88. Hortner M, Nielsch U, Mayr LM, Heinrich PC, Haan S. A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. Eur. J. Biochem. 269(10), 2516-2526 (2002).
89. Capello D, Deambrogi C, Rossi D et al. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br. J. Haematol. 141(4), 504-511 (2008).
90. Jost E, do O N, Dahl E et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ ABL-negative myeloproliferative disorders. Leukemia 21(3), 505-510 (2007).
91. Teofili L, Martini M, Cenci T et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int. J. Cancer 123(7), 1586-1592 (2008).
92. Quentmeier H, Geffers R, Jost E et al. SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia 22(12), 2169-2175 (2008).
93. Haan S, Ferguson P, Sommer U et al. Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. J. Biol. Chem. 278(34), 31972-31979 (2003).
94. Hookham M, Elliott J, Suessmuth Y et al. The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 109(11), 4924-4929 (2007).
95. Rudd CE. Lnk adaptor: novel negative regulator of B cell lymphopoiesis. Sci. STKE 2001(85), PE1 (2001).
96. Takaki S, Sauer K, Iritani BM et al. Control of B cell production by the adaptor protein lnk. Definition of a conserved family of signal-modulating proteins. Immunity 13(5), 599-609 (2000).
97. Takaki S, Morita H, Tezuka Y, Takatsu K. Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J. Exp. Med. 195(2), 151-160 (2002).
98. Velazquez L, Cheng AM, Fleming HE et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J. Exp. Med. 195(12), 1599-1611 (2002).
99. Tong W, Lodish HF. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J. Exp. Med. 200(5), 569-580 (2004).
100. Buza-Vidas N, Antonchuk J, Qian H et al. Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK. Genes Dev. 20(15), 2018-2023 (2006).
101. Tong W, Zhang J, Lodish HF. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 105(12), 4604-4612 (2005).
102. Bersenev A, Wu C, Balcerek J, Tong W. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J. Clin. Invest. 118(8), 2832-2844 (2008).
103. Gery S, Gueller S, Chumakova K, Kawamata N, Liu L, Koeffler HP. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood 110(9), 3360-3364 (2007).
104. Simon C, Dondi E, Chaix A et al. Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. Blood 112(10), 4039-4047 (2008).
105. Oh ST, Simonds EF, Jones C et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood DOI: blood-2010-02-270108 (2010) (Epub ahead of print).
106. Schmidt MH, Dikic I. The Cbl interactome and its functions. Nat. Rev. Mol. Cell Biol. 6(12), 907-918 (2005).
107. Langdon WY, Hartley JW, Klinken SP, Ruscetti SK, Morse HC 3rd. v-Cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas. Proc. Natl Acad. Sci. USA 86(4), 1168-1172 (1989).
108. Caligiuri MA, Briesewitz R, Yu J et al. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood 110(3), 1022-1024 (2007).
109. Sargin B, Choudhary C, Crosetto N et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood 110(3), 1004-1012 (2007).
110. Dunbar AJ, Gondek LP, O'Keefe CL et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 68(24), 10349-10357 (2008).
111. Grand FH, Hidalgo-Curtis CE, Ernst T et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113(24), 6182-6192 (2009).
112. Makishima H, Cazzolli H, Szpurka H et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J. Clin. Oncol. 27(36), 6109-6116 (2009).
113. Sanada M, Suzuki T, Shih LY et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 460(7257), 904-908 (2009).
114. Loh ML, Sakai DS, Flotho C et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 114(9), 1859-1863 (2009).
115. Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernández-Luna JL. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N. Engl. J. Med. 338(9), 564-571 (1998).
116. Plo I, Nakatake M, Malivert L et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 112(4), 1402-1412 (2008).
117. Zhao R, Oxley D, Smith T, Follows GA, Green AR, Alexander DR. DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH. PLoS Biol. 5(1), e1 (2007).
118. Zhao R, Follows GA, Beer PA et al. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N. Engl. J. Med. 359(26), 2778-2789 (2008).
119. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N. Engl. J. Med. 362(4), 369-370 (2010).
120. Pardanani A, Lasho TL, Finke CM et al. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia DOI: 10.1038/ leu.2010.77 (2010) (Epub ahead of print).
121. Jager R, Gisslinger H, Berg T et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms at transformation to acute myeloid leukemia. Blood 114, 181 (2009) (Abstract 435).
122. Mullighan CG, Miller CB, Radtke I et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453 (7191), 110-114 (2008).
123. Jamieson CH, Ailles LE, Dylla SJ et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351(7), 657-667 (2004).
124. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer 7(9), 673-683 (2007).